Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers

Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and <= 64, Plus Revaccination

ClinicalTrials.gov ID: NCT00889889

Public ClinicalTrials.gov record NCT00889889. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 14, 2026, 8:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Cell-Derived Trivalent Subunit Influenza Vaccine in Subjects Aged >= 18 Years and <= 64 Years During Two Consecutive Years.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Immunogenicity and safety of a cell-derived influenza vaccine in adults aged \>= 18 and \<= 64 years, plus revaccination

Study identification

NCT ID
NCT00889889
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Abbott Biologicals
Industry
Enrollment
1,270 participants

Conditions and interventions

Conditions

Interventions

Biological

Eligibility (public fields only)

Age range
18 Years to 64 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2009
Primary completion
Dec 31, 2010
Completion
Dec 31, 2010
Last update posted
Oct 24, 2013

2009 – 2011

United States locations

U.S. sites
15
U.S. states
10
U.S. cities
15
Facility City State ZIP Site status
Site Reference ID/Investigator# 45690 Jacksonville Florida 32216
Site Reference ID/Investigator# 45687 Pembroke Pines Florida 33024
Site Reference ID/Investigator# 45697 South Miami Florida 33143
Site Reference ID/Investigator# 45691 Lenexa Kansas 66219
Site Reference ID/Investigator# 45689 Overland Park Kansas 66212
Site Reference ID/Investigator# 45694 Wichita Kansas 67207
Site Reference ID/Investigator# 45682 Lexington Kentucky 40509
Site Reference ID/Investigator# 45684 Kansas City Missouri 64114
Site Reference ID/Investigator# 45685 Omaha Nebraska 68134
Site Reference ID/Investigator# 45686 Las Vegas Nevada 89104
Site Reference ID/Investigator# 45688 Raleigh North Carolina 27612
Site Reference ID/Investigator# 45696 Nashville Tennessee 37203
Site Reference ID/Investigator# 45683 Austin Texas 78705
Site Reference ID/Investigator# 45695 Fort Worth Texas 76135
Site Reference ID/Investigator# 45692 Salt Lake City Utah 84124

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00889889, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 24, 2013 · Synced Sep 14, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00889889 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →